NCITA comment article published in the British Journal of Cancer
NCITA* have recently published a Comment article “Introduction to the National Cancer Imaging Translational Accelerator (NCITA): a UK-wide infrastructure for multicentre clinical translation of cancer imaging biomarkers” in the British Journal of Cancer https://www.nature.com/articles/s41416-021-01497-5#Sec1 on Tuesday 27 July 2021.
This Comment article provides a comprehensive overview of the NCITA infrastructure and its goals to establish standardised protocols and locked-down quality-assured processes for clinical imaging biomarker qualification and a federated research data repository for secure data storage and sharing between multiple study sites.
NCITA infrastructure support is available to clinical researchers in academia and industry through NCITA’s study adoption process.
International partners are also eligible to apply. While cancer imaging studies are a key focus, clinical research studies in other disease areas involving AI algorithm development, training and validation will also be considered for adoption by NCITA.
NCITA are also engaging with NHS Trusts, pharmaceutical companies, medical imaging and nuclear medicine companies as well as funding bodies and patient groups, to develop consensus guidelines on how the imaging biomarker development pathway can be improved to achieve more efficient translation of quality-assured imaging biomarkers into clinical practice.
*National Cancer Imaging Translational Accelerator (NCITA) is a national UK-wide medical imaging infrastructure which aims to accelerate the standardisation and translation of cancer imaging biomarkers for clinical use. NCITA is led in Manchester by Professor James O’Connor who is a member of the NCITA Governance Group and is the NCITA Training Group Chair. Professor James O’Connor is project lead together with Professor Geoff Parker at UCL for the NCITA Exemplar FOAM study which is establishing the multi-platform feasibility of Oxygen Enhanced MRI (OE-MRI) for adaptive radiotherapy planning in patients with non-small cell lung cancer.